Vega Therapeutics Inc.

Plenty of biopharmaceutical firms continue to struggle to raise fresh capital under current financial market conditions with drug developer valuations still well below what they were a few years ago a

The end of each year brings a surge in venture capital funding announcements as biopharmaceutical companies and investors seek to close as many deals as possible before everyone takes off for the Dece